SIBO recurrence rate

SIBO Recurrence Rate: Screening the Host After the Kill

After breath tests normalized with rifaximin, SIBO recurred in 12.6% of patients at three months, 27.5% at six months and 43.7% at nine months. Those checkpoints make defensible recheck points, and chronic proton pump inhibitor use, which raised recurrence odds more than threefold, is the one predictor a practice can modify.

Eradication succeeds often enough that recurrence gets treated as bad luck. The recurrence data describe a predictable curve, modifiable predictors and a gap between clearance and response that a follow-up plan should be built around.

The SIBO recurrence rate is the number that should shape follow-up after eradication, and it is rarely discussed when the first course is prescribed. The video The Weeds Were Never the Problem, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, argues that antibiotic clearance without a plan for what repopulates the bowel produces a shortening cycle. The ruling it lands on is to judge the result on function. For a screening practice that raises concrete questions: when to recheck, which predictors to act on, what microbial testing cannot say, and which host measures document the patient rather than the organisms.

The SIBO recurrence rate curve and its checkpoints

In the recurrence cohort, patients whose breath test normalized after a week of rifaximin tested positive again in 12.6% at three months, 27.5% at six months and 43.7% at nine months, with symptoms rising in parallel with test positivity. Follow-up ended at nine months, so the second year is unmeasured. The retreatment trial in diarrhea-predominant IBS saw 44.1% respond to the open-label phase, and 692 of 1,074 responders, 64.4%, relapsed within eighteen weeks. Retreatment of responders beat placebo modestly, 38.1% against 31.5%, in a population preselected for having responded once.

Those intervals give follow-up its structure. Three, six and nine months are where recurrence was actually measured, which makes them defensible recheck points and natural anchors for standing orders rather than waiting for symptoms to force a visit.

Predictors that are not organisms

Chronic proton pump inhibitor use raised the odds of recurrence more than threefold, prior appendectomy nearly sixfold, and each added year of age carried an odds ratio of 1.09 (95% CI 1.02-1.16). Of the three, only the acid suppression is modifiable, which puts deprescribing review squarely in the recurrence plan. The medication decision belongs to the prescribing clinician after weighing the original indication; the point is that it is reviewed deliberately rather than renewed by default.

There is a structural reason the review rarely happens. A branded antibiotic course arrives with registration trials, packaging and detailing, while fermented food and medication reconciliation have no sponsor and no representative. The kill acquires a guideline line; repopulation acquires a shrug at discharge. Practices that want a different recurrence curve have to build the unglamorous half into workflow, because no one will market it to them.

Clearance is not response

Pooled across 32 studies and 1,331 patients, rifaximin eradication runs 70.8% by intention to treat and 72.9% per protocol, with adverse events at 4.6%. Heterogeneity sits at I2 87-91% across the pooled estimates, and the authors grade the underlying study quality as generally poor. Co-therapy was among three covariates independently associated with higher eradication, a signpost rather than a protocol. The decisive figure is different: among patients whose overgrowth was demonstrably cleared, only 67.7% improved symptomatically. A third leave with a normal test and persistent illness.

That gap is why a normal breath test should not close the episode. Symptom trajectory and host function need their own documentation, recorded at the same checkpoints as the repeat breath test.

What microbial testing cannot tell you

Stool microbiome sequencing, breath testing and fecal calprotectin are different tests performed elsewhere. Measura [Cardiometabolic and Autonomic Health Analysis] does not offer them. Their limits matter for interpretation regardless of who runs them. In a capsule transplant trial in irritable bowel syndrome, fecal diversity rose while quality of life at three months favored placebo. In healthy adults, more than doubling fiber from 21.5 to 45.1 g per day left alpha diversity unchanged cohort-wide, while 6.3 servings a day of fermented food raised diversity and lowered 19 of 93 inflammatory serum proteins, although the primary outcome was not met. Membership is not function.

The post-antibiotic literature explains why. After four days of meropenem, gentamicin and vancomycin in healthy young men, composition approached baseline within about six weeks, yet nine species present in every subject beforehand remained undetectable in most at 180 days, and resistance-gene carriers were selected during the refill. The best post-antibiotic probiotic study found capsule strains delayed native mucosal recovery compared with unaided reconstitution, while autologous stool restored it within days; it measured composition and transcriptome, not clinical end points.

Host function as the follow-up record

If the ruling is function, the record should measure the host. The first brain sits upstream of the second, and persistent metaflammation does not respect the boundary between them. Laboratory panels cover the metabolic and inflammatory picture that a gut-focused workup tends to omit. Bioimpedance body composition and indirect calorimetry document muscle and fat compartments and measured resting energy expenditure in patients whose intake has been restricted across months of symptoms. Heart rate variability records autonomic tone. None of these detects overgrowth, and none substitutes for a repeat breath test; they document how the patient is functioning at the same checkpoints.

Operationally, that means a standing order triggered at the final antibiotic dose, host measures at baseline and at the recurrence checkpoints, and medication review folded into the annual wellness visit. The same measures support documentation for MIPS and quality reporting. Primary studies and their limits are in the book companion, and testing before treating covers the measurement that should precede the first course.

Frequently asked questions

References

• Lauritano, E. C., Gabrielli, M., Scarpellini, E., Lupascu, A., Novi, M., Sottili, S., Vitale, G., Cesario, V., Serricchio, M., Cammarota, G., Gasbarrini, G., & Gasbarrini, A. (2008). Small intestinal bacterial overgrowth recurrence after antibiotic therapy. The American Journal of Gastroenterology, 103(8), 2031-5. https://doi.org/10.1111/j.1572-0241.2008.02030.x
• Lembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016). Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology, 151(6), 1113-1121. https://doi.org/10.1053/j.gastro.2016.08.003
• Gatta, L., & Scarpignato, C. (2017). Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology & Therapeutics, 45(5), 604-616. https://doi.org/10.1111/apt.13928
• Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018). Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut, 67(12), 2107-2115. https://doi.org/10.1136/gutjnl-2018-316434
• Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., Robinson, J. L., Elias, J. E., Sonnenburg, E. D., Gardner, C. D., & Sonnenburg, J. L. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell, 184(16), 4137-4153.e14. https://doi.org/10.1016/j.cell.2021.06.019
• Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., Pyl, P. T., Coelho, L. P., Yang, H., Wang, J., Typas, A., Nielsen, M. F., Nielsen, H. B., Bork, P., Wang, J., … Pedersen, O. (2018). Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology, 3(11), 1255-1265. https://doi.org/10.1038/s41564-018-0257-9
• Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., Zur, M., Regev-Lehavi, D., Ben-Zeev Brik, R., Federici, S., Horn, M., Cohen, Y., Moor, A. E., Zeevi, D., Korem, T., Kotler, E., Harmelin, A., Itzkovitz, S., Maharshak, N., … Elinav, E. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell, 174(6), 1406-1423.e16. https://doi.org/10.1016/j.cell.2018.08.047
• Tariq, R., Pardi, D. S., & Khanna, S. (2023). Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 16, 17562848231174293. https://doi.org/10.1177/17562848231174293

Related reading

• CIRS Diagnosis: What the Mold Evidence Supports in Screening
• Postcholecystectomy Diarrhea: A Measurement-First Workup
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.